Dok H. Yoon

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 286 publications

Role of Autologous Stem Cell Transplantation in Transplant-Eligible Dialysis-Dependent Multiple Myeloma Patients.

Role of Autologous Stem Cell Transplantation in Transplant-Eligible Dialysis-Dependent Multiple Myeloma Patients.

Journal: Cancer research and treatment
Published: May 12, 2026

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Journal: Blood
Published: April 30, 2026

Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.

Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.

Journal: British journal of haematology
Published: April 08, 2026

Imaging predictors of response and outcomes after CAR T-cell therapy in lymphoma: from clinical trials to real-world practice.

Imaging predictors of response and outcomes after CAR T-cell therapy in lymphoma: from clinical trials to real-world practice.

Journal: Frontiers in immunology
Published: April 03, 2026

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.

Journal: Clinical hematology international
Published: March 31, 2026

Prognostic impact of blood Epstein-Barr virus-DNA in patients with peripheral T-cell lymphoma, not otherwise specified.

Prognostic impact of blood Epstein-Barr virus-DNA in patients with peripheral T-cell lymphoma, not otherwise specified.

Journal: British journal of haematology
Published: March 18, 2026

The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.

The prognostic factors and immune microenvironment of primary plasma cell leukemia: the KMMWP-2204 study.

Journal: Haematologica
Published: February 25, 2026

Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination.

Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination.

Journal: Annals of hematology
Published: January 29, 2026

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Journal: Blood advances
Published: January 16, 2026

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Journal: Blood advances
Published: January 16, 2026

Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study.

Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study.

Journal: Cancers
Published: January 06, 2026

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Journal: Blood
Published: January 05, 2026
Showing 1-12 of 286

Last Updated: 09/26/2026